Elevating Psychosocial Care With the First-Ever World Psycho-Oncology Day

News
Video

World Psycho-Oncology Day is an initiative aimed at spreading awareness and pursuing the further integration of psychosocial care into cancer treatment.

The International Psycho-Oncology Society (IPOS) announced that April 9, 2025, is the first-ever World Psycho-Oncology Day (WPOD), a day with the primary goal of spreading awareness of the importance of psychosocial care in oncology.

Following the announcement, CancerNetwork® interviewed Cristiane Decat Bergerot, PhD, MS, a psychologist, the head of supportive care at Grupo Oncoclinicas in Brazil, and a member of IPOS, who mentioned the focus on honoring Jimmie C. Holland, MD, a pioneer in the psycho-oncology space and the inaugural chief of the Psychiatry Services department at Memorial Sloan Kettering Cancer Center in 1977. At the time, this department was the first of its kind at any cancer center in the world.

The IPOS website officially lists 5 major goals of WPOD: raising awareness, honoring Jimmie Holland, engaging stakeholders, promoting action, and supporting fundraising efforts.

Transcript:

[WPOD] was created by the [IPOS] and its federation members to elevate global awareness of the psychological and emotional impact of cancer. It will be celebrated on April 9 starting in 2025, in honor of Jimmie Holland, MD. Our primary goals will be to raise awareness of the role of psycho-oncology in cancer care, to honor Jimmie Holland, to engage stakeholders, to promote psycho-oncology, and to promote actions for the integration of psychosocial care into national and global cancer guidelines. We also aim to support fundraising efforts to advance psycho-oncology initiatives. We aim to empower patients, caregivers, and health care professionals, fostering a future where psychosocial support is an integral part of oncology worldwide.

Jimmie Holland was a pioneer who transformed cancer care by bringing attention to the psychological and emotional challenges [that] patients [have]. She founded the field of psycho-oncology, demonstrating that mental health is an integral part of cancer treatment. Her groundbreaking research led to the development of distress screening guidelines, which are now a standard part of cancer care. Beyond research, Holland was a tireless advocate for integrating psychosocial care into cancer treatment globally. Through her leadership at [IPOS], she helped establish psycho-oncology as a recognized discipline, influencing policies and training programs worldwide. Her legacy continues to shape how we care for our patients today, ensuring that emotional and psychological well-being are prioritized alongside physical health. [WPOD] is a tribute to her contributions, celebrating her vision and reinforcing the importance of holistic cancer care.

Reference

World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Related Content